Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 1/20 | 0.50 |
| ▸ | GCGR | P47871 | 9/20 | 0.49 |
| ▸ | GIPR | P48546 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655011 | 1.00 | GCG (0.50) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2654456 | 1.00 | GCG (0.50) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2651638 | 0.94 | GCGR (0.49) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2651583 | 0.94 | GCGR (0.49) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2654285 | 0.94 | GCG (0.48) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2652475 | 0.94 | GCGR (0.49) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2653041 | 0.94 | GCGR (0.49) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2652203 | 0.94 | GCGR (0.50) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2650317 | 0.94 | GCG (0.49) | GCGGCGRGIPRMEN1KMT2A | |
| SCHEMBL2654487 | 0.91 | MEN1 (0.48) | GCGGCGRGIPRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | claimed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |